Cardiorenal syndrome clinical trial end points.

Published

Journal Article (Review)

Cardiorenal syndrome is a focus of interest in heart failure because of the substantial associated morbidity and mortality. Recent clinical trials of novel heart failure therapies targeting the interdependence of cardiac and renal dysfunction have failed to show significant benefits with respect to many end points. The heterogeneity of this patient population and the lack of standardized clinical trial end points complicate forward progress. This article reviews the end points evaluated in key clinical trials of cardiorenal syndrome and synthesizes recent discussions about the appropriateness of end points for future trials.

Full Text

Duke Authors

Cited Authors

  • Mentz, RJ; O'Connor, CM

Published Date

  • October 2011

Published In

Volume / Issue

  • 7 / 4

Start / End Page

  • 519 - 528

PubMed ID

  • 21925435

Pubmed Central ID

  • 21925435

International Standard Serial Number (ISSN)

  • 1551-7136

Digital Object Identifier (DOI)

  • 10.1016/j.hfc.2011.06.012

Language

  • eng

Conference Location

  • United States